4D Molecular Therapeutics (FDMT) Profit After Tax (2020 - 2026)
4D Molecular Therapeutics' (FDMT) quarterly Profit After Tax came in at -$68.8 million in Q1 2026, down 43.33% year-on-year from -$121.3 million in Q1 2025, and down 454.49% on a QoQ basis from $19.4 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Profit After Tax (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 7 years of Profit After Tax data on file, last reported at -$68.8 million in Q1 2026.
- On a quarterly basis, Profit After Tax fell 43.33% year-over-year to -$68.8 million in Q1 2026; TTM through Mar 2026 was -$160.9 million, a 8.81% increase from a year earlier, with the FY2025 full-year figure at -$140.1 million, up 12.9% from the prior year.
- Profit After Tax for Q1 2026 stood at -$68.8 million, down from $19.4 million in the prior quarter.
- Over the last five years, Profit After Tax for FDMT reached as high as $19.4 million in Q4 2025 and fell as low as -$68.8 million in Q1 2026.
- Historically, Profit After Tax has averaged -$34.0 million across 5 years, with a median of -$32.3 million in 2023.
- Across the five-year window, Profit After Tax sank 327.49% in 2024 and jumped 139.05% in 2025, its largest moves.
- Year by year, Profit After Tax stood at -$27.4 million in 2022, then dropped by 17.91% to -$32.3 million in 2023, then plunged by 53.86% to -$49.7 million in 2024, then surged by 139.05% to $19.4 million in 2025, then plunged by 454.49% to -$68.8 million in 2026.
- Per Business Quant data, the three most recent Profit After Tax figures were -$68.8 million in Q1 2026, $19.4 million in Q4 2025, and -$56.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | 4D Molecular Therapeutics | 706.51 Mn | 315.62 Mn | - | -68.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -68.76 Mn |
| Dec 31, 2025 | 19.40 Mn |
| Sep 30, 2025 | -56.88 Mn |
| Jun 30, 2025 | -54.66 Mn |
| Mar 31, 2025 | -47.97 Mn |
| Dec 31, 2024 | -49.67 Mn |
| Sep 30, 2024 | -43.84 Mn |
| Jun 30, 2024 | -34.95 Mn |
| Mar 31, 2024 | -32.40 Mn |
| Dec 31, 2023 | -32.28 Mn |
| Sep 30, 2023 | -10.26 Mn |
| Jun 30, 2023 | -29.62 Mn |
| Mar 31, 2023 | -28.68 Mn |
| Dec 31, 2022 | -27.38 Mn |
| Sep 30, 2022 | -25.69 Mn |
| Jun 30, 2022 | -28.09 Mn |
| Mar 31, 2022 | -26.34 Mn |
| Dec 31, 2021 | -25.08 Mn |
| Sep 30, 2021 | -22.24 Mn |
| Jun 30, 2021 | -7.59 Mn |